title: Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
abstract: Bile acids are ligands for the nuclear hormone receptor, farnesoid X receptor (FXR). The bile acid-FXR interaction regulates bile acid synthesis, transport, and cholesterol metabolism. Recently, bile acid-FXR regulation has been reported to play an integral role in both hepatic and intestinal inflammation, and in atherosclerosis. In this study, we found that FXR knockout mice had more disease severity in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Obeticholic acid (6α-ethyl-chenodeoxycholic acid, 6-ECDCA), a synthetic FXR agonist, is an orally available drug that is currently in clinical trials for the treatment of inflammatory diseases such as alcoholic hepatitis, nonalcoholic steatohepatitis, and primary biliary cirrhosis. When we treated mice exhibiting established EAE with 6-ECDCA, or the natural FXR ligand chenodeoxycholic acid (CDCA), clinical disease was ameliorated by (i) suppressing lymphocyte activation and proinflammatory cytokine production; (ii) reducing CD4(+) T cells and CD19(+) B cell populations and their expression of negative checkpoint regulators programmed cell death protein 1 (PD1), programmed death-ligand 1 (PD-L1), and B and T lymphocyte attenuator (BTLA); (iii) increasing CD8(+) T cells and PD1, PDl-1, and BTLA expression; and (iv) reducing VLA-4 expression in both the T- and B-cell populations. Moreover, adoptive transfer of 6-ECDCA- or CDCA-treated donor cells failed to transfer disease in naive recipients. Thus, we show that FXR functions as a negative regulator in neuroinflammation and we highlight that FXR agonists represent a potential previously unidentified therapy for MS.
authors.affiliation: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford CA 94305.
authors.forename: Peggy P
authors.initials: PP
authors.lastname: Ho
authors.affiliation: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford CA 94305 steinman@stanford.edu.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Steinman
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001647:Bile Acids and Salts / Q000378:metabolism*; D002635:Chenodeoxycholic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D007274:Injections, Intraperitoneal; D008024:Ligands; D008213:Lymphocyte Activation / Q000187:drug effects; D018345:Mice, Knockout; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000378:metabolism; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D001647:Bile Acids and Salts; D002635:Chenodeoxycholic Acid; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D000099150:Receptor, Farnesoid X-Activated; C464660:obeticholic acid
keywords: bile acid agonist; experimental autoimmune encephalomyelitis; farnesoid X receptor; multiple sclerosis; obeticholic acid
references.citation: Ann Neurol. 1986 Jun;19(6):578-87
references.pmid: 3524414
references.citation: EMBO J. 1992 Nov;11(11):3887-95
references.pmid: 1396582
references.citation: Gastroenterology. 2013 Sep;145(3):574-82.e1
references.pmid: 23727264
references.citation: Nat Rev Immunol. 2002 Oct;2(10):748-59
references.pmid: 12360213
references.citation: J Lipid Res. 1977 Mar;18(2):135-53
references.pmid: 557521
references.citation: Expert Rev Clin Pharmacol. 2016;9(1):13-26
references.pmid: 26549695
references.citation: Nat Immunol. 2007 Mar;8(3):239-45
references.pmid: 17304234
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2428-33
references.pmid: 14983026
references.citation: Immunol Rev. 2009 May;229(1):88-100
references.pmid: 19426216
references.citation: Nature. 2002 Nov 7;420(6911):78-84
references.pmid: 12422218
references.citation: Science. 1999 May 21;284(5418):1362-5
references.pmid: 10334992
references.citation: Cell. 1995 Jun 2;81(5):687-93
references.pmid: 7774010
references.citation: J Neuroimmunol. 2005 Nov;168(1-2):65-75
references.pmid: 16098614
references.citation: J Clin Invest. 2006 Apr;116(4):1037-44
references.pmid: 16543951
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3668-73
references.pmid: 14990788
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3920-5
references.pmid: 16473946
references.citation: Am J Pathol. 1988 Mar;130(3):443-54
references.pmid: 2450462
references.citation: Mol Cell. 1999 May;3(5):543-53
references.pmid: 10360171
references.citation: Front Biosci. 1998 Feb 15;3:d176-93
references.pmid: 9450986
references.citation: Front Immunol. 2015 Aug 21;6:418
references.pmid: 26347741
references.citation: Immunol Rev. 2010 Jul;236:219-42
references.pmid: 20636820
references.citation: Neurol Neuroimmunol Neuroinflamm. 2015 Nov 04;2(6):e170
references.pmid: 26587555
references.citation: J Autoimmun. 2010 Aug;35(1):33-44
references.pmid: 20172692
references.citation: Mol Pharmacol. 2010 Oct;78(4):617-30
references.pmid: 20631053
references.citation: J Exp Med. 2010 Aug 2;207(8):1599-608
references.pmid: 20624891
references.citation: J Med Chem. 2002 Aug 15;45(17):3569-72
references.pmid: 12166927
references.citation: Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1519-28
references.pmid: 20631352
references.citation: Circulation. 2009 Mar 3;119(8):1135-45
references.pmid: 19221221
references.citation: Biochim Biophys Acta. 2010 Jul;1801(7):683-92
references.pmid: 20399894
references.citation: J Exp Med. 2009 Sep 28;206(10):2079-89
references.pmid: 19737866
references.citation: J Immunol. 2004 May 1;172(9):5790-8
references.pmid: 15100326
references.citation: J Biol Chem. 2003 Jan 24;278(4):2563-70
references.pmid: 12421815
references.citation: J Exp Med. 2001 Sep 3;194(5):669-76
references.pmid: 11535634
references.citation: Ann Neurol. 2002 Jun;51(6):694-702
references.pmid: 12112074
references.citation: J Exp Med. 2006 Feb 20;203(2):401-12
references.pmid: 16476765
references.citation: Mol Immunol. 2007 Feb;44(6):1436-45
references.pmid: 16837048
references.citation: Acta Neuropathol. 1988;75(6):566-76
references.pmid: 3259787
references.citation: J Med Chem. 2004 Aug 26;47(18):4559-69
references.pmid: 15317466
references.citation: Lancet. 2015 Mar 14;385(9972):956-65
references.pmid: 25468160
references.citation: Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):717-26
references.pmid: 12006382
references.citation: Nat Immunol. 2003 Jul;4(7):670-9
references.pmid: 12796776
references.citation: J Immunol. 2009 Nov 15;183(10):6657-66
references.pmid: 19880446
references.citation: J Immunol. 2002 Mar 1;168(5):2508-15
references.pmid: 11859145
references.citation: Annu Rev Immunol. 2005;23:683-747
references.pmid: 15771584
references.citation: Drugs. 2013 Sep;73(13):1463-81
references.pmid: 23912625
references.citation: J Immunol. 2009 Nov 15;183(10):6251-61
references.pmid: 19864602
references.citation: Annu Rev Immunol. 1990;8:579-621
references.pmid: 2188675
references.citation: Immunol Rev. 2009 May;229(1):114-25
references.pmid: 19426218
references.citation: J Exp Med. 2000 Aug 7;192(3):393-404
references.pmid: 10934227
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11
references.pmid: 16410358
references.citation: J Immunol. 2004 Jul 15;173(2):945-54
references.pmid: 15240681
references.citation: J Immunol. 2001 Jun 15;166(12):7579-87
references.pmid: 11390514
references.citation: Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2606-11
references.pmid: 18029909
references.citation: J Exp Med. 2007 Feb 19;204(2):321-30
references.pmid: 17261635
references.citation: J Biol Chem. 2002 Jun 14;277(24):21453-7
references.pmid: 11967257
references.citation: Ann Transl Med. 2015 Jan;3(1):5
references.pmid: 25705637
references.citation: Neurosci Lett. 1999 Jul 9;269(2):71-4
references.pmid: 10430507